Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma
R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities
Simple Summary Secondary amplifications/copy number changes of the gene MET (MET
protocol oncogene) play a significant role in the development of resistance to targeted drugs …
protocol oncogene) play a significant role in the development of resistance to targeted drugs …
MET-targeted therapies and clinical outcomes: a systematic literature review
Y Dong, J Xu, B Sun, J Wang, Z Wang - Molecular Diagnosis & Therapy, 2022 - Springer
Introduction Numerous therapeutic agents specifically targeting the mesenchymal-epithelial
transition (MET) oncogene are being developed. Objective The aim of the current review …
transition (MET) oncogene are being developed. Objective The aim of the current review …
Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors
Tyrosine kinase inhibitors (TKIs), as an important class of chemotherapeutic drugs, induce
apoptosis by altering the path of the cellular signal, resulting in cell death. However, some …
apoptosis by altering the path of the cellular signal, resulting in cell death. However, some …
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
MET amplification (MET amp), a mechanism of acquired resistance to EGFR tyrosine kinase
inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) …
inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) …
[HTML][HTML] Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
MSC Li, KKS Mok, TSK Mok - Annals of Translational Medicine, 2023 - ncbi.nlm.nih.gov
Methods We searched all original papers and reviews on targeted therapy and
immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search …
immunotherapy in non-small cell lung cancer (NSCLC) using PubMed in June 2022. Search …
NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease
A Michelotti, M de Scordilli, E Bertoli… - International Journal of …, 2022 - mdpi.com
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during …
S Muto, T Matsubara, T Inoue, H Kitamura… - International Journal of …, 2023 - Springer
The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …
the addition of cancer-specific risk factors to those already present for CKD. In this review …
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT …
Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective
MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant …
MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant …
Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study
T Hirakawa, M Doi, K Hamai, R Katsura, S Miyake… - Respiratory …, 2023 - Elsevier
Background Few studies have been conducted on comprehensive genomic profiling (CGP)
panels in Japanese patients with thoracic malignancies after completing standard treatment …
panels in Japanese patients with thoracic malignancies after completing standard treatment …